Immune checkpoint inhibitors (ICIs) are new and promising therapeutic agents for non-small
cell lung cancer (NSCLC). However, along with demonstrating remarkable efficacy, ICIs can …

Immune checkpoint inhibitors (ICIs) have been applied to clinical practice and achieved
significant therapeutic benefit in a variety of human malignancies. These drugs not only …

Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that can occur
after initiation of anti–programmed death 1/programmed death ligand 1 immune checkpoint …

Background Immune checkpoint inhibitors (ICIs) have led to dramatic improvements in
survival a subset of patients with non-small cell lung cancer (NSCLC); however, they have …

Abstract Objectives Immune checkpoint inhibitors (ICIs) can cause pneumonitis in lung
cancer patients. We aimed to identify the clinical and radiologic characteristics, incidence …

Immune checkpoint inhibitors (ICIs) are newer, immunotherapy-based drugs that have been
shown to improve survival in advanced non-small cell lung cancer (NSCLC). Unlike …

Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely
observed (< 5%). ICI-P is more often observed in patients with nonsmall cell lung cancer …

Background Immune checkpoint inhibitors (ICIs) are standard treatments for advanced non-
small cell lung cancer and have expanded use in small cell lung cancer. Although generally …

Background: Recently, immune checkpoint inhibitors (ICIs) have been proved one of the
most promising anti-cancer therapy, series clinical trials have confirmed their efficacy. But …

Abstract Background: Immune checkpoint inhibitors (ICIs) can lead to one of the common
and quite serious immune-related adverse events (irAEs) in a real-world setting, namely …